BL-B01D1 binds EGFR/HER3 on tumor cells, is internalized, and releases a topoisomerase I inhibitor (brengitecan) that induces DNA damage and apoptosis. Topoisomerase I is the intracellular enzymatic payload target, not the surface antigen recognized by the drug; cells expressing only topoisomerase I are not selectively killed.